Protagen AG and MicroDiscovery GmbH Cooperate in Biomarker Development
Want to listen to this article for FREE?
Complete the form below to unlock access to ALL audio articles.
Read time: Less than a minute
Dortmund based Protagen AG, a specialist in in-vitro diagnostics and GMP-conform protein analytics and MicroDiscovery GmbH, a bioinformatics company based in Berlin, have started a cooperation to identify and validate biomarkers for medically relevant diseases.
"Our proprietary technology platform UNIarray® and MicroDiscovery's certified software solutions for the analysis of complex marker panels complement each other perfectly," states Dr. Peter Schulz-Knappe, CSO and Executive Vice President Diagnostics of Protagen AG and adds: "The cooperation strengthens our position in biomarker development and supports the efficient development of marketable products."
Dr. Arif Malik, CEO of MicroDiscovery GmbH, confirms: "Our experience in analyzing clinical studies for multiplex assays and array data perfectly fits with Protagen's established screening platform. This illustrates the value of MicroDiscovery's bioinformatics methods and software solutions for the development of new diagnostics."
"Our proprietary technology platform UNIarray® and MicroDiscovery's certified software solutions for the analysis of complex marker panels complement each other perfectly," states Dr. Peter Schulz-Knappe, CSO and Executive Vice President Diagnostics of Protagen AG and adds: "The cooperation strengthens our position in biomarker development and supports the efficient development of marketable products."
Dr. Arif Malik, CEO of MicroDiscovery GmbH, confirms: "Our experience in analyzing clinical studies for multiplex assays and array data perfectly fits with Protagen's established screening platform. This illustrates the value of MicroDiscovery's bioinformatics methods and software solutions for the development of new diagnostics."
